Search results
Results From The WOW.Com Content Network
Project MKUltra[a] was a human experimentation program designed and undertaken by the U.S. Central Intelligence Agency (CIA) to develop procedures and identify drugs that could be used during interrogations to weaken individuals and force confessions through brainwashing and psychological torture. [1] The term MKUltra is a CIA cryptonym: "MK ...
Denied trade screening is the process of screening parties involved in both domestic and export transactions for the purpose of complying with the safety standards of the U.S. Government. Effective trade screening not only includes denied parties but also controlled products and embargoed or sanctioned countries.
This class of drugs are mimics of serotonin that activate 5-HT receptor subtypes that release norepinephrine and dopamine. 2C-B-BZP. 3-Chlorophenylpiperazine, meta-Chlorophenylpiperazine, mCPP. 4-Fluorophenylpiperazine, para-Fluorophenylpiperazine, pFPP, 4-FPP, Fluoperazine, Flipiperazine.
Amgen. non-small cell lung cancer with KRAS G12C mutation. Avapritinib. Blueprint Medicines Corp. granted for two indications: mast cell leukemia and advanced systemic mastocytosis. Belumosudil. Kadmon Pharmaceuticals. chronic graft-versus-host disease. Pembrolizumab.
1-Testosterone. Tetrahydrogestrinone. Trenbolone. Drugs with similar structures and biological activity are also banned because new designer drugs of this sort are always being developed in order to beat the drug tests. Caffeine, a stimulant known to improve performance, is currently not on the banned list.
1. receptor antagonist. Neurokinin 1 (NK1) antagonists (-pitants) are a novel class of medications that possesses unique antidepressant, [1][2] anxiolytic, [3] and antiemetic properties. NK-1 antagonists boost the efficacy of 5-HT3 antagonists to prevent nausea and vomiting. The discovery of neurokinin 1 (NK 1) receptor antagonists was a ...
Dizocilpine (INN), also known as MK-801, is a pore blocker of the NMDA receptor, a glutamate receptor, discovered by a team at Merck in 1982. [1] Glutamate is the brain's primary excitatory neurotransmitter. The channel is normally blocked with a magnesium ion and requires depolarization of the neuron to remove the magnesium and allow the ...
Soluble guanylate cyclase (sGC) stimulators are a class of drugs developed to treat heart failure, pulmonary hypertension, and other diseases. The first-in-class medication was riociguat, approved in 2013 for pulmonary hypertension. [1][2] They have also been investigated for hypertension, systemic sclerosis, and sickle cell disease. [3][1]